Rexahn: Corporate Presentation (Rexahn Pharmaceuticals, Inc) - Feb 17, 2013 - "Treatment with Archexin in combination with gemcitabine provided a median survival of 9.1 months compared to the historical survival data of 5.65 months (Burris et al., 1997, J. Clin Oncol 15:2403) for standard single agent gemcitabine therapy"
P2a data • Oncology
|